Drug Trial Radar · NCT00060944
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Sep 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
271
Actual
Start
May 2003
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- PharmaMar
- First posted
- May 19, 2003
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
Conditions
- Liposarcoma
- Leiomyosarcoma
Interventions
YondelisDrug
1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
YondelisDrug
0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
DexamethasoneDrug
Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
DexamethasoneDrug
Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Progression- Independent ReviewTime frame: From randomization to the first documentation of disease progression or death due to progressive disease, whichever occurs first, assessed up to 5 years
Locations
39 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Aurora, Colorado
Site not named
Coeur d'Alene, Idaho
Site not named
Park Ridge, Illinois
Site not named
Indianapolis, Indiana
Site not named
Louisville, Kentucky
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Rochester, Minnesota
Site not named
Newark, New Jersey
Site not named
New York, New York
Site not named
Cleveland, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Site not named
Seattle, Washington
Site not named
Milwaukee, Wisconsin
Site not named
East Melbourne, Australia
Site not named
Newcastle, Australia
Site not named
Perth, Australia
Site not named
Woodville, Australia
Site not named
Leuven, Belgium
Site not named
Edmonton, Canada
Site not named
Calgary, Alberta, Canada
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Lyon, France
Site not named
Villejuif, France
Site not named
Düsseldorf, Germany
Site not named
Moscow, Russia
Site not named
Obninsk, Russia
Site not named
Saint Petersburg, Russia
Site not named
Samara, Russia
Site not named
Barcelona, Spain
Site not named
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.